Figure 5.

DAC inhibits the growth of cholangiocarcinoma mouse xenografts. (A) Tumor xenografts were established in mice by implanting TFK-1 cells into the upper right flank of the individual mice. Treatment with DAC or control was initiated when the tumors became barely palpable. Animals were treated with 0.8 mg/kg DAC (n=5) or vehicle alone (4% DMSO; n=5) by intraperitoneal injection daily for 14 days. Tumor volume was evaluated every two days until the end of the treatment. Data are presented as the mean ± standard deviation. (B) Representative mice from control and treated groups. (C) Survival was evaluated from the first day of treatment to mortality using the Kaplan-Meier method. ^*P<0.05, vs. control. DAC, decitabine.